Literature DB >> 3839802

Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency.

D T Bonthron, A F Markham, D Ginsburg, S H Orkin.   

Abstract

Deficiency of adenosine deaminase (ADA) is the cause of an autosomal recessive form of immunodeficiency. We sought to define, at a molecular level, the mutations responsible for ADA deficiency in the cell line GM-1715, derived from an immunodeficient patient. Full-length complementary DNA (cDNA) for ADA was synthesized and cloned from the cell line. Sequence analysis of the clones revealed a point mutation in codon 101 (CGG to CAG) that predicts an amino acid change from arginine to glutamine. Southern blot analysis, based on silent polymorphisms in the cDNA sequence, indicated that only one of the defective alleles of the GM-1715 line had been sequenced. The mutation that was identified appears to be responsible for the loss of function in this allele, since the predicted primary structure of the enzyme is otherwise entirely normal.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3839802      PMCID: PMC423929          DOI: 10.1172/JCI112050

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Efficient isolation of genes by using antibody probes.

Authors:  R A Young; R W Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

Review 2.  Biochemistry of diseases of immunodevelopment.

Authors:  D W Martin; E W Gelfand
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

3.  High-efficiency cloning of full-length cDNA.

Authors:  H Okayama; P Berg
Journal:  Mol Cell Biol       Date:  1982-02       Impact factor: 4.272

4.  New M13 vectors for cloning.

Authors:  J Messing
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  A phenotypically normal revertant of an adenosine deaminase-deficient lymphoblast cell line.

Authors:  J Uberti; W D Peterson; J J Lightbody; R M Johnson
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

6.  Buffer gradient gels and 35S label as an aid to rapid DNA sequence determination.

Authors:  M D Biggin; T J Gibson; G F Hong
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

7.  Immunoreactive protein in adenosine deaminase deficient human lymphoblast cell lines.

Authors:  D A Wiginton; J J Hutton
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

8.  Adenosine deaminase messenger RNAs in lymphoblast cell lines derived from leukemic patients and patients with hereditary adenosine deaminase deficiency.

Authors:  G S Adrian; J J Hutton
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

9.  Genetic heterogeneity in partial adenosine deaminase deficiency.

Authors:  R Hirschhorn; F Martiniuk; V Roegner-Maniscalco; A Ellenbogen; J L Perignon; T Jenkins
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

10.  Solid phase phosphotriester synthesis of large oligodeoxyribonucleotides on a polyamide support.

Authors:  A F Markham; M D Edge; T C Atkinson; A R Greene; G R Heathcliffe; C R Newton; D Scanlon
Journal:  Nucleic Acids Res       Date:  1980-11-25       Impact factor: 16.971

View more
  29 in total

1.  Adenosine deaminase (ADA) deficiency due to deletion of the ADA gene promoter and first exon by homologous recombination between two Alu elements.

Authors:  M L Markert; J J Hutton; D A Wiginton; J C States; R E Kaufman
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

Review 2.  Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind.

Authors:  Bertrand Boisson; Pierre Quartier; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2015-01-31       Impact factor: 7.486

3.  Identification and characterization of nine RFLPs at the adenosine deaminase (ADA) locus.

Authors:  S Tzall; A Ellenbogen; F Eng; R Hirschhorn
Journal:  Am J Hum Genet       Date:  1989-06       Impact factor: 11.025

4.  The CpG dinucleotide and human genetic disease.

Authors:  D N Cooper; H Youssoufian
Journal:  Hum Genet       Date:  1988-02       Impact factor: 4.132

Review 5.  The map of chromosome 20.

Authors:  N E Simpson
Journal:  J Med Genet       Date:  1988-12       Impact factor: 6.318

6.  Identification of a point mutation resulting in a heat-labile adenosine deaminase (ADA) in two unrelated children with partial ADA deficiency.

Authors:  R Hirschhorn; S Tzall; A Ellenbogen; S H Orkin
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

7.  Correct splicing despite mutation of the invariant first nucleotide of a 5' splice site: a possible basis for disparate clinical phenotypes in siblings with adenosine deaminase deficiency.

Authors:  F X Arredondo-Vega; I Santisteban; S Kelly; C M Schlossman; D T Umetsu; M S Hershfield
Journal:  Am J Hum Genet       Date:  1994-05       Impact factor: 11.025

8.  Severe combined immune deficiency due to a homozygous 3.2-kb deletion spanning the promoter and first exon of the adenosine deaminase gene.

Authors:  T M Berkvens; E J Gerritsen; M Oldenburg; C Breukel; J T Wijnen; H van Ormondt; J M Vossen; A J van der Eb; P Meera Khan
Journal:  Nucleic Acids Res       Date:  1987-11-25       Impact factor: 16.971

9.  Mutations in the human adenosine deaminase gene that affect protein structure and RNA splicing.

Authors:  A L Akeson; D A Wiginton; J C States; C M Perme; M R Dusing; J J Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

10.  Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype.

Authors:  I Santisteban; F X Arredondo-Vega; S Kelly; A Mary; A Fischer; D S Hummell; A Lawton; R U Sorensen; E R Stiehm; L Uribe
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.